{"id":"NCT01064401","sponsor":"Biogen","briefTitle":"Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis","officialTitle":"Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2014-03","completion":"2014-07","firstPosted":"2010-02-08","resultsPosted":"2016-07-11","lastUpdate":"2016-07-11"},"enrollment":1841,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing-Remitting Multiple Sclerosis"],"interventions":[{"type":"BIOLOGICAL","name":"BIIB019 (Daclizumab High Yield Process)","otherNames":["DAC HYP"]},{"type":"DRUG","name":"Interferon beta-1a Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Interferon beta-1a","otherNames":["Avonex","IFN β-1a"]},{"type":"DRUG","name":"Daclizumab High Yield Process Placebo","otherNames":[]}],"arms":[{"label":"Daclizumab High Yield Process 150 mg SC","type":"EXPERIMENTAL"},{"label":"IFN β-1a 30 µg IM","type":"ACTIVE_COMPARATOR"}],"summary":"The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting multiple sclerosis.\n\nThe secondary study objectives are to test the superiority of DAC HYP compared to IFN β-1a in slowing functional decline and disability progression and maintaining quality of life in this participant population.","primaryOutcome":{"measure":"Adjusted Annualized Relapse Rate (ARR)","timeFrame":"Up to 144 weeks","effectByArm":[{"arm":"Interferon Beta-1a","deltaMin":0.393,"sd":null},{"arm":"Daclizumab High Yield Process","deltaMin":0.216,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":14},"locations":{"siteCount":228,"countries":["United States","Argentina","Australia","Brazil","Canada","Czechia","Denmark","Finland","France","Georgia","Germany","Greece","Hungary","India","Ireland","Israel","Italy","Mexico","Moldova","Poland","Romania","Russia","Serbia","Spain","Sweden","Switzerland","Ukraine","United Kingdom"]},"refs":{"pmids":["37652990","37072219","28984179","28485186","28104250","27251051","26444729"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":194,"n":922},"commonTop":["Multiple sclerosis relapse","Influenza like illness","Nasopharyngitis","Headache","Upper respiratory tract infection"]}}